Everything we do here at Xstrahl is possible because of our excellent team. Our medical systems help to treat non-melanoma skin cancer (NMSC), keloids, inflammatory disorders, and so much more. [...]

Everything we do here at Xstrahl is made possible by our highly skilled and helpful staff. Our research customers continue to speak highly of the application and technical support they receive, [...]

When you choose a medical equipment provider, you’re not just choosing the product, you’re choosing the people. Customers routinely tell us that it’s the people of Xstrahl that [...]

NIH Funding Opportunities The National Institute of Health has announced three (3) opportunities for varying levels of funding as part of the Office of Research Infrastructure Program. Complete [...]

RADiant on display on booth no. 2561 February 28t, 2019 – Xstrahl Medical, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and dermatological conditions, is [...]

February 20th, 2019 – Xstrahl Medical, global leader in superficial radiotherapy devices and advanced radiation research systems, is celebrating 20 years of delivering technical training courses [...]

February 6th, 2019 – A leading dermatology center in Tennessee has commenced advanced skin radiotherapy treatments using the new RADiant treatment system from Xstrahl Medical, global leader in [...]

Xstrahl Medical, global leader in superficial radiotherapy devices and advanced radiation research systems, has been named the best specialty radiotherapy systems manufacturer in the 2018 Global [...]

Xstrahl Medical and Electronica Y Medicina, S.A. (EYMSA) are announcing a partnership to supply next generation superficial radiotherapy systems for the treatment of non-melanoma skin cancers. [...]

Xstrahl Medical, global leaders in superficial radiotherapy devices and advanced radiation research systems, has appointed Neil Madle as Commercial Director – Radiotherapy. Based at [...]

Nasal function and cosmesis are important considerations in the quality of life for nasal ala skin cancer patients. Surgery involves tissue loss, which is likely to lead to impaired function and undesired cosmetic results. Superficial radiotherapy can be an effective alternative without these negative side effects, if administered in proper doses. The case studies featured […]

Over his career, Dr. Steven Davis, medical director of The Dermatology & Laser Center of San Antonio has performed over 25,000 skin cancer operations. While surgery is still the primary treatment, it’s not always the best option for the patient, especially people on blood thinners, with diabetes, or cancers on certain parts of the skin. […]

Xstrahl’s new mouse immobilization suite gives you the flexibility you need for your experiments. With over 85% of image guided irradiation publications utilizing SARRP, Xstrahl has always brought research success and flexibility. Mirroring clinical treatments is part of the SARRP DNA and just like in the clinic, set-up is a key part of dose optimization. […]

As we navigate this season of social distancing, we are doing what we can to be available to our network. Part of this includes making more online resources available, especially in light of the many cancelled and postponed events. Even as parts of the industry are paused during this time, we hope to continue expanding […]

For a subset of cancers, the exciting world of ion beam, proton beam and FLASH radiotherapy have presented new opportunities to deliver high doses of ionizing radiation to tumors, with the potential to increasingly spare normal tissue. As these therapies move into more routine clinical practice, it is critical to optimize and validate current treatment […]

With the rates of skin cancers ever increasing, especially in places with high sun prevalence, treatment of these conditions can cause not only a demand on resources, but there is a lack of unified response and the best way to treat. This is why Prof. Gerald Fogarty of GenesisCare in Australia has used the Xstrahl […]

October 3rd, 2019 Xstrahl and Washington DC-based C&C Irradiator Service are announcing a partnership to supply next generation X-ray irradiator systems to replace cesium sources across the U.S. Used throughout the world, with hundreds in the United States, Cesium-137 is a radioactive source used in equipment such as older generation radiotherapy systems and irradiators. However, […]

Histone acetyltransferase 1 (Hat1) is responsible for the acetylation of newly synthesized histone H4 on lysines 5 and 12 during the process of chromatin assembly. To understand the broader biological role of Hat1, we have generated a conditional mouse knockout model of this enzyme. We previously reported that Hat1 is required for viability and important […]

September 18th Open call for original research articles and current reviews dedicated to the development and application of animal models in radiotherapy research for publication in Cancers.   Animal models are essential tools in radiotherapy research that have played critical roles in developing our understanding of tumour and normal tissue response. With recent advances in […]

September 13th, 2019 New X-ray radiotherapy image guidance system and SARRP beamline research platform among advanced new solutions showcased on Xstrahl booth (No. 4028) at American Society for Radiation Oncology annual meeting in Chicago, September 15th-18th. Xstrahl, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and dermatological conditions, is spotlighting its full […]